Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zafirlukast for Breast Capsular Contracture
NCT02950480Phase 2Terminated
- Sponsor
- University of California, San Francisco
- Start
- Mar 2017
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of zafirlukast in capsular contracture, sponsored by University of California, San Francisco. Primary endpoint: Capsular Thickness. Started Mar 2017; status: terminated.
02
Drugs
zafirlukast
03
Conditions
capsular contracture
Beyond the preview
Go deeper on NCT02950480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02950480.